[
  {
    "ts": null,
    "headline": "Trump: Cost of Ozempic Could Be $150. Dr. Oz: Not Yet.",
    "summary": "President Trump said in the Oval Office on Thursday that the cost of Ozempic, or \"the fat loss drug,\" could be $150—or \"much lower\" than the current cost.  Dr. Mehmet Oz, the Centers for Medicare & Medicaid Services administrator, jumped in to say the cost of those drugs hadn't yet been negotiated.  The administration is negotiating the price of drugs with several pharmaceutical companies and has already struck deals with Pfizer and AstraZeneca.",
    "url": "https://finnhub.io/api/news?id=3d6fdd3d62cdaaa34e84bc4bc578b8edc1cd5f2d0efd735b362fe5b8b5206eeb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760648941,
      "headline": "Trump: Cost of Ozempic Could Be $150. Dr. Oz: Not Yet.",
      "id": 137121989,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "President Trump said in the Oval Office on Thursday that the cost of Ozempic, or \"the fat loss drug,\" could be $150—or \"much lower\" than the current cost.  Dr. Mehmet Oz, the Centers for Medicare & Medicaid Services administrator, jumped in to say the cost of those drugs hadn't yet been negotiated.  The administration is negotiating the price of drugs with several pharmaceutical companies and has already struck deals with Pfizer and AstraZeneca.",
      "url": "https://finnhub.io/api/news?id=3d6fdd3d62cdaaa34e84bc4bc578b8edc1cd5f2d0efd735b362fe5b8b5206eeb"
    }
  },
  {
    "ts": null,
    "headline": "RBC Warns Gilead (GILD) Faces Risk from Trump’s Price Cut Target",
    "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best stocks to buy according to Jim Simons’ Renaissance Technologies. On October 1, RBC analysts stated that Gilead Sciences, Inc. (NASDAQ:GILD) may face a negative impact if its key HIV medication, Biktarvy, is targeted by the proposed price cuts mentioned by President Trump. During an announcement related […]",
    "url": "https://finnhub.io/api/news?id=d6309782940414e45994057909ffb7045df75c136861f03637b4ab2060e69563",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760644261,
      "headline": "RBC Warns Gilead (GILD) Faces Risk from Trump’s Price Cut Target",
      "id": 137121976,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best stocks to buy according to Jim Simons’ Renaissance Technologies. On October 1, RBC analysts stated that Gilead Sciences, Inc. (NASDAQ:GILD) may face a negative impact if its key HIV medication, Biktarvy, is targeted by the proposed price cuts mentioned by President Trump. During an announcement related […]",
      "url": "https://finnhub.io/api/news?id=d6309782940414e45994057909ffb7045df75c136861f03637b4ab2060e69563"
    }
  },
  {
    "ts": null,
    "headline": "TrumpRx Aims at Reduced Prices and Misses",
    "summary": "TrumpRx Aims at Reduced Prices and Misses",
    "url": "https://finnhub.io/api/news?id=cf2d54aecbb0b6eefbfb46887d54f729580ea4ac4a2d675814507c50ccba1328",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760631480,
      "headline": "TrumpRx Aims at Reduced Prices and Misses",
      "id": 137139307,
      "image": "",
      "related": "PFE",
      "source": "DowJones",
      "summary": "TrumpRx Aims at Reduced Prices and Misses",
      "url": "https://finnhub.io/api/news?id=cf2d54aecbb0b6eefbfb46887d54f729580ea4ac4a2d675814507c50ccba1328"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Strikes $70B Deal with Trump--But Warns China Is Racing Ahead in Biotech War",
    "summary": "CEO Albert Bourla sounds alarm on U.S. vaccine policy chaos, tariff risks, and China's pharma power play.",
    "url": "https://finnhub.io/api/news?id=6eb7e7fa24f7acf903613a36da9d91cc94b5e64cb8c323bf32a1b2b69937c7bd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760625953,
      "headline": "Pfizer Strikes $70B Deal with Trump--But Warns China Is Racing Ahead in Biotech War",
      "id": 137121991,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "CEO Albert Bourla sounds alarm on U.S. vaccine policy chaos, tariff risks, and China's pharma power play.",
      "url": "https://finnhub.io/api/news?id=6eb7e7fa24f7acf903613a36da9d91cc94b5e64cb8c323bf32a1b2b69937c7bd"
    }
  },
  {
    "ts": null,
    "headline": "Inside Yahoo Finance Invest 2025: AI stock bubble, Trump tariff realities, a Fed under siege, and another crypto boom",
    "summary": "With markets having a huge year, Yahoo Finance presents its annual marquee event, Invest. The timing couldn't be more perfect as investors aim to build more wealth headed into 2026.",
    "url": "https://finnhub.io/api/news?id=da9059bf3480d93a026c51bfe1633f89ed48ea632b7b5ce4c72160ff3fcc14ed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760619634,
      "headline": "Inside Yahoo Finance Invest 2025: AI stock bubble, Trump tariff realities, a Fed under siege, and another crypto boom",
      "id": 137104279,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "With markets having a huge year, Yahoo Finance presents its annual marquee event, Invest. The timing couldn't be more perfect as investors aim to build more wealth headed into 2026.",
      "url": "https://finnhub.io/api/news?id=da9059bf3480d93a026c51bfe1633f89ed48ea632b7b5ce4c72160ff3fcc14ed"
    }
  },
  {
    "ts": null,
    "headline": "5 Things Retirees Need To Know About the New Trump Drug Program",
    "summary": "Will TrumpRx help cut prescription costs for uninsured retirees? Learn how this new drug program could impact retirees' prescription budgets come 2026.",
    "url": "https://finnhub.io/api/news?id=f63dd4a5aa7196fc9f78fff3c2390b0be3e63e0884ccef70f348ca0f6202958f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760616730,
      "headline": "5 Things Retirees Need To Know About the New Trump Drug Program",
      "id": 137104606,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Will TrumpRx help cut prescription costs for uninsured retirees? Learn how this new drug program could impact retirees' prescription budgets come 2026.",
      "url": "https://finnhub.io/api/news?id=f63dd4a5aa7196fc9f78fff3c2390b0be3e63e0884ccef70f348ca0f6202958f"
    }
  },
  {
    "ts": null,
    "headline": "A Once-in-a-Decade Investment Opportunity: 1 Pharmaceutical Stock to Buy Now Hand Over Fist and Hold for Years",
    "summary": "It's the best time in a while to scoop up shares of this stock from the discount bin.",
    "url": "https://finnhub.io/api/news?id=4a09912c3e229d692cf2403bd64e1c850d2af3e51985e0ccd20c6e8af208ed24",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760616720,
      "headline": "A Once-in-a-Decade Investment Opportunity: 1 Pharmaceutical Stock to Buy Now Hand Over Fist and Hold for Years",
      "id": 137104607,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "It's the best time in a while to scoop up shares of this stock from the discount bin.",
      "url": "https://finnhub.io/api/news?id=4a09912c3e229d692cf2403bd64e1c850d2af3e51985e0ccd20c6e8af208ed24"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer’s Q3 2025 Earnings: What to Expect",
    "summary": "Pfizer is expected to report its third-quarter results next month, and analysts are projecting a double-digit decline in its earnings.",
    "url": "https://finnhub.io/api/news?id=03b827335da557b40a51ba986c5df46dd5be345806c640347a9e37dd6715f3a0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760609839,
      "headline": "Pfizer’s Q3 2025 Earnings: What to Expect",
      "id": 137104608,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer is expected to report its third-quarter results next month, and analysts are projecting a double-digit decline in its earnings.",
      "url": "https://finnhub.io/api/news?id=03b827335da557b40a51ba986c5df46dd5be345806c640347a9e37dd6715f3a0"
    }
  },
  {
    "ts": null,
    "headline": "Seeking Gold And Retirement Income? IGLD Is The Answer",
    "summary": "FT Vest Gold Strategy Target Income ETF delivers high yield and gold exposure, balancing income and safety in your portfolio. See here for more IGLD ETF.",
    "url": "https://finnhub.io/api/news?id=4bf8ad6e12e7098cf705b459243fa78986dd5585fd42fb39fb4a67b790a852db",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760606100,
      "headline": "Seeking Gold And Retirement Income? IGLD Is The Answer",
      "id": 137104249,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/185303843/image_185303843.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "FT Vest Gold Strategy Target Income ETF delivers high yield and gold exposure, balancing income and safety in your portfolio. See here for more IGLD ETF.",
      "url": "https://finnhub.io/api/news?id=4bf8ad6e12e7098cf705b459243fa78986dd5585fd42fb39fb4a67b790a852db"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Don't Forget About Value During AI Frenzy",
    "summary": "Pfizer's revenue has stabilized, and a recent drug pricing deal with the US government reduces political uncertainty. Find out why PFE stock is a Strong Buy.",
    "url": "https://finnhub.io/api/news?id=97e0f1197458430ed173619194b3258379538ceee5fd393d034adfb3e3d8b4c0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760591303,
      "headline": "Pfizer: Don't Forget About Value During AI Frenzy",
      "id": 137103327,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418907713/image_1418907713.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer's revenue has stabilized, and a recent drug pricing deal with the US government reduces political uncertainty. Find out why PFE stock is a Strong Buy.",
      "url": "https://finnhub.io/api/news?id=97e0f1197458430ed173619194b3258379538ceee5fd393d034adfb3e3d8b4c0"
    }
  }
]